402 related articles for article (PubMed ID: 25435121)
21. Neuroblastoma in adolescents: the Italian experience.
Conte M; Parodi S; De Bernardi B; Milanaccio C; Mazzocco K; Angelini P; Viscardi E; Di Cataldo A; Luksch R; Haupt R
Cancer; 2006 Mar; 106(6):1409-17. PubMed ID: 16475209
[TBL] [Abstract][Full Text] [Related]
22. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
[TBL] [Abstract][Full Text] [Related]
23. Towards a turning point of neuroblastoma therapy.
Tonini GP; Nakagawara A; Berthold F
Cancer Lett; 2012 Dec; 326(2):128-34. PubMed ID: 22922304
[TBL] [Abstract][Full Text] [Related]
24. Recent insights into the biology of neuroblastoma.
Schleiermacher G; Janoueix-Lerosey I; Delattre O
Int J Cancer; 2014 Nov; 135(10):2249-61. PubMed ID: 25124476
[TBL] [Abstract][Full Text] [Related]
25. Outcomes in multifocal neuroblastoma as part of the neurocristopathy syndrome.
Williams P; Wegner E; Ziegler DS
Pediatrics; 2014 Aug; 134(2):e611-6. PubMed ID: 25070313
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic mutations of ALK in neuroblastoma.
Ogawa S; Takita J; Sanada M; Hayashi Y
Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
28. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.
Yue Z; Gao C; Xing T; Zhao W; Duan C; Wang X; Jin M; Su Y
Pediatr Blood Cancer; 2023 May; 70(5):e30261. PubMed ID: 36815592
[TBL] [Abstract][Full Text] [Related]
29. Loss of whole chromosome X predicts prognosis of neuroblastoma patients with numerical genomic profile.
Parodi S; Pistorio A; Erminio G; Ognibene M; Morini M; Garaventa A; Gigliotti AR; Haupt R; Frassoni F; Pezzolo A
Pediatr Blood Cancer; 2019 May; 66(5):e27635. PubMed ID: 30688024
[TBL] [Abstract][Full Text] [Related]
30. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
[TBL] [Abstract][Full Text] [Related]
31. Ten challenges in the management of neuroblastoma.
Gains J; Mandeville H; Cork N; Brock P; Gaze M
Future Oncol; 2012 Jul; 8(7):839-58. PubMed ID: 22830404
[TBL] [Abstract][Full Text] [Related]
32. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
33. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
34. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes in patients with stage IV neuroblastoma.
Escobar MA; Grosfeld JL; Powell RL; West KW; Scherer LR; Fallon RJ; Rescorla FJ
J Pediatr Surg; 2006 Feb; 41(2):377-81. PubMed ID: 16481255
[TBL] [Abstract][Full Text] [Related]
36. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
[TBL] [Abstract][Full Text] [Related]
37. Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A
Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094
[TBL] [Abstract][Full Text] [Related]
38. Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
Pediatr Blood Cancer; 2006 Mar; 46(3):278-84. PubMed ID: 16124002
[TBL] [Abstract][Full Text] [Related]
39. Updates in Diagnosis, Management, and Treatment of Neuroblastoma.
Swift CC; Eklund MJ; Kraveka JM; Alazraki AL
Radiographics; 2018; 38(2):566-580. PubMed ID: 29528815
[TBL] [Abstract][Full Text] [Related]
40. Molecular genetics of neuroblastoma and the implications for clinical management: a review of the MSKCC experience.
Mora J; Gerald WL; Qin J; Cheung NK
Oncologist; 2001; 6(3):263-8. PubMed ID: 11423673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
